CLAIM #19907 · DE (DE) · 2023Q4 earnings call · Nov 22, 2023 · due Dec 31, 2025
“We are targeting a significant push for premium into the installed base in 2025, supported by our Solutions as a Service business model.”
Brent Norwood · Head of IR
In context
“ear of high margins and reduced decrementals relative to our historical performance. I'd like now to switch the focus over to our tech stack. Brent, could you give us an update on the business model and where we stand across See & Spray, autonomy and the latest Gen 5 display and operating system? Brent Norwood: Sure. We've made some big strides across our entire tech product portfolio this year, with much of the focus on our retrofit solutions or what we refer to as precision upgrades. With See & Spray, which is our down payment on Sense & Act technologies, we successfully launched See & Spray Ultimate for model year 2024 and have seen significant interest in our limited release of See & Spray Premium, the retrofit kit, which can be applied all the way back to model year 2018 sprayers. We are targeting a significant push for premium into the installed base in 2025, supported by our Solutions as a Service business model. For See & Spray Premium, we've kept the up-front capital cost for hardware and installation to a minimum, followed by a per-acre use model that aligns our monetization with our customers' value. Meanwhile, our autonomy journey is progressing nicely with plans for acreage expansion through our paid pilots in 2024. Our 2023 pilots generated substantial insights in model training, while our key metrics improved significantly year-over-year for KPIs like uptime without intervention, mean time between interventions and reductions in false positives. The progress here will set us up for broader commercialization with opportunities to accelerate utilization through retrofitting autonomy in the installed base of our tractors. What we started seeing is that when a customer tries out new preci”
Verify independently
SEC filings for DE ↗ · Claim quote is verbatim from the 2023Q4 earnings call.